European Companies Search Engine
EU funding (€14M): Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment. Hor22 Jan 2021 EU Research and Innovation programme "Horizon"
Overview
Text
Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment.
More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached. AI-Mind will radically shorten this journey to 1 week through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk. Our AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools. The AI-Mind Connector identifies dysfunctional brain networks. The AI-Mind Predictor assesses demen-tia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables. Our aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform. The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical cen-tres, who closely collaborate with 3 SMEs contributing unique technologies, an established data govern-ance body, and Alzheimer Europe. Together, they plan to deliver a medical device of class 2b that can reach TRL7 by the end of the project. AI-Mind represents a major step forward in the risk assessment of dementia. Clinicians will promptly advise therapies to delay the onset of disease, and patients will enjoy independent lives for longer. By offering a globally accessible, cheap and precise tool for dementia pre-diction, AI-Mind will improve the health care system and boost innovation by shifting the R&D of phar-maceutical organisations and other companies to preventive diagnostic methods and therapies for dementia.
Funded Companies:
| Company name | Funding amount |
| AALTO KORKEAKOULUSAATIO sr | €773,438 |
| ACCELOPMENT SCHWEIZ AG | €851,250 |
| Alzheimer Europe | €269,375 |
| Brainsymph AS | €1,045,814 |
| DNV AS | €438,895 |
| F. HOFFMANN-LA ROCHE AG | €0.00 |
| HUS-YHTYMA | €1,131,350 |
| Irccs SAN Raffaele Roma Srl | €543,438 |
| Lurtis Rules SL | €994,375 |
| Neuroconnect Srl | €571,750 |
| Oslomet - Storbyuniversitetet | €984,050 |
| Oslo Universitetssykehus HF | €3,025,904 |
| PRE Diagnostics AS | €0.00 |
| ROCHE DIAGNOSTICS INTERNATIONAL AG | €0.00 |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | €336,163 |
| STICHTING RADBOUD UNIVERSITEIT | €0.00 |
| TALLINN UNIVERSITY | €443,125 |
| Universidad Complutense de Madrid | €1,169,125 |
| Universidad Politecnica de Madrid | €0.00 |
| Universita Cattolica Del Sacro Cuore | €944,938 |
| Universitetet I Oslo | €475,875 |
Source: https://cordis.europa.eu/project/id/964220
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "AALTO KORKEAKOULUSAATIO sr - EU funding (€14M): Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment."
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
